Second, despite the IDH1R132H mutation being the most influential genetic factor for postoperative oncological outcomes of gliomas, information concerning other potential factors such as the chromosomal 1p/19q codeletion, IDH2 or MGMT mutation, and ATRX mutation was not considered. The gene discussed is IDH2; the disease is central nervous system cancer.